Tyme Technologies Inc

Tyme Technologies — Investor Presentation (September 2017)

27 slides from Tyme Technologies's investor presentation, Sep 11, 2017

  1. Slide 1: The Future of Cancer Treatments

    Exhibit 99.1 TYMEO) the FUTURE of CANCER TREATMENTS SEPTEMBER 2017

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement Certain statements in this presentation and associated oral statements are "forward-looking statements" under the Private Securities Litigation Reform Act. These forward-looking statements are based on our current expectations and beliefs and are subject to a number of risk fac

  3. Slide 3: Tyme Overview

    Tyme Overview Selectively target cancer through its altered metabolism and dependence on tyrosine Use a tumor’s natural function to cause apoptosis from oxidative stress Complete and partial responses with monotherapy in 13 different types of progressive, metastatic cancer Median survival in metasta

  4. Slide 4: SM-88 and Tyme at a Glance

    SM-88 and Tyme at a Glance Oral tyrosine-based therapy for cancer Over 5 years of clinical data in more than 100 metastatic subjects No drug-related SAEs to date First human study, completed (n=30) Monotherapy in end stage progressive metastatic cancers Median OS of 27.5 months 90% clinical benefit

  5. Slide 5: ECOG Performance Status and First Human Study Summary

    ECOG Performance Status* Following 1 Cycle of SM-88 (n = 30) Number of Subjects Score Start End 0 1 14 1 15 14 2 10 2 3 3 0 4 1 0 5 0 0 Average 1.6 0.6 * Eastern Cooperative Oncology Group Performance Score score: 0 (asymptomatic), 1-3 (symptomatic) , 4 (bedbound), 5 (death). SM-88: First Human Stud

  6. Slide 6: FHS Median Overall Survival 27.5 months

    FHS Median Overall Survival 27.5 months All Subjects (n = 30), Monotherapy with SM-88 90% of subjects experienced clinical benefit (CR, PR or SD)1 All subjects entered with progressing metastatic disease OS substantially exceeded expectations Subjects entered with 3-6 months expected survival Treatm

  7. Slide 7: Stable Disease Designation with SM-88

    Subject 040 KG failed two lines of systemic therapy in addition to surgery before entering the trial. Subject is still alive more than five years after initiating SM-88 therapy and has had no other cancer therapies Standardized uptake value (SUV) is a measurement of tumor metabolism using positron e

  8. Slide 8: SM-88: First Human Study Safety Profile

    SM-88: First Human Study Safety Profile Median SM-88 exposure: 16.3 weeks, (range: 6-61 weeks) Adverse Events Reported in the First Human Study (n=30)1 Adverse EventGrade 1Grade 2 Grade 3/4 Total 29 (97%)1 (3%) - 30 (100%) 13 (43%)4 (13%) - 17 (57%) 3 (10%)1 (3%) - 4 (13%) 1 (3%)- - 1 (3%) 1 (3%)- -

  9. Slide 9: Common Ties Between Cancers

    Common Ties Between Cancers Discovered in the 1920s Shows that cancer produces energy differently than normal cells Relies on a more primitive metabolic process, called aerobic glycolysis Highly inefficient use of glucose Produces a high level of free radicals (“ROS”) Drives reliance on amino acids

  10. Slide 10: Breaking the Metabolic Circuit of Cancer

    Breaking the Metabolic Circuit of Cancer 3) Protective Mucin Layer Compromised 4) Cell Death From Oxidative Stress Immune Response Free Radicals (ROS) 2) Protein Synthesis Fails 1) Induce Uptake of Tyme’s Dysfunctional Tyrosine

  11. Slide 11: SM-88 Composition and Function

    Dysfunctional Tyrosine Derivative SM-88 Composition and Function Non-nutritive tyrosine analogs disrupt cancer’s creation of proteins, including mucin Rapamycin* mTOR inhibitor decreases insulin function and increases tyrosine uptake * Microdose: <25% of recommended therapeutic dosing levels CELL DE

  12. Slide 12: Clinical Development Pipeline

    Clinical Development Pipeline Program Formulation Cancer Indication Pre-IND Phase I Phase II Phase III SM-88 Oral Prostate, recurrent non-metastatic Pancreatic, metastatic 3rd Indication, Metastatic Injectable Digestively compromised patients Nasal Glioma Transdermal Breast Tyrosine-bound Melanin Or

  13. Slide 13: Current and Planned Trials

    Current and Planned Trials TYMEO

  14. Slide 14: Rationale for Prostate Cancer Application

    Rationale for Prostate Cancer Application Third most prevalent cancer 160,000 new cases in US in 2017 27,000 deaths in US in 2017 Multibillion dollar drug market Radiotherapy Prostatectomy Market Stats Lower side effect profile Maintain testosterone levels Chronic administration as maintenance thera

  15. Slide 15: Phase Ib/II Biomarker-Recurrent Prostate Cancer Trial Design

    No progression events Decrease CTC Maintain testosterone Maintain quality of life No additional toxic therapy Improve PSA doubling Phase Ib/II Biomarker-Recurrent, Non-Metastatic Prostate Cancer Trial Design Phase Ib: dose-escalation phase (n=4), completed Jan 2017 Both 230mg and 460mg tyrosine dose

  16. Slide 16: Summary of Ongoing Phase Ib/II Prostate Trial

    Summary of Ongoing Phase Ib/II Trial in Biomarker Recurrent Prostate Cancer Efficacy Endpoint Evaluable response (n=9) Radiographic progression free survival (rPFS) 100.0% Improvement in circulating tumor cells All subjects Need for subsequent toxic therapy None Average improvement in PSA doubling 1

  17. Slide 17: Rapid Circulating Tumor Cell Response

    Rapid Circulating Tumor Cell Response CTCs are tumor cells that are carried in the blood and may be an early indicator of metastatic disease All subjects had an improvement in CTC levels and 67% (6/9) had an 80% or greater decline Indexed Circulating Tumor Cell Levels Per Patient Month

  18. Slide 18: Preliminary Safety Results

    No grade 2 or higher drug-related adverse events >55 months of cumulative daily oral dosing experience Maintained quality of life in patient reported intimacy outcomes In comparison, QOL in this area would be expected to decline if patient was chemically castrated with ADT therapy Phase Ib/II Biomar

  19. Slide 19: Pancreatic Cancer Statistics

    Pancreatic Cancer Statistics 1.American Cancer Society Current prognosis for pancreatic cancer is 80% mortality in first year Five-year survival rate for metastatic stage of 1% Standard-of-care results from recent clinical trials: First-line Abraxane + gemcitibine: median OS of 8.5m and CR+PR of 23%

  20. Slide 20: Existing SM-88 Data for Pancreatic Cancer

    Existing SM-88 Data for Pancreatic Cancer 1.Note: Patients in the compassionate use program may differ from treatment protocol in the First Human Study Summary of Metastatic Pancreatic Cancer Patients Treated with SM-88 First Human Study Patient Overall Survival (months) Duration on SM-88 (months) R

  21. Slide 21: Planned Phase II Trial: Metastatic Pancreatic Cancer

    Planned Phase II Trial: Metastatic Pancreatic Cancer Structure: Open-Label Enrollment: ~100 patients (2 stages) End Points: PFS, OS, Response Rate Stage 2 Stage 1 Indication Refractory Metastatic Pancreatic Cancer Patients (2L/3L) Interim Analysis SM-88 Monotherapy Sites: ~35 across North America CR

  22. Slide 22: Historical Results Offer Multiple Paths Forward

    Historical Results Offer Multiple Paths Forward CR/PR Shown in 13 Different Tumor Types Source: American Cancer Society. Objective Response Rate (“ORR”) based on imaging analysis using RECIST 1.1 criteria. Includes both First Human Study and Compassionate Use Patients. Primary Disease 2016 U.S. Data

  23. Slide 23: Corporate Profile

    Corporate Profile TYMEO

  24. Slide 24: Corporate History

    Corporate History Virtual company funded by founders Mission to help patients that have failed or refused all other options Treated >80 advanced metastatic cancer patients with a New York hospital Established proof-of-concept First outside funding Launched Phase Ib/II prostate trial under Tyme IND I

  25. Slide 25: Management & Board

    Management & Board Founders Other Executives Board & MAB Chairman, CEO & CSO Steve Hoffman Authored >30 issued patents Director & COO Michael Demurjian >25 years repeated entrepreneur President & CFO Ben Taylor Chief Medical Officer Dr. Giuseppe Del Priore Chief Scientific Affairs Officer Jon Eckard

  26. Slide 26: Recent Achievements and Upcoming Objectives

    Recent Achievements and Upcoming Objectives Positive interim Phase Ib/II prostate cancer data presented at ESMO 2017 Five data presentations/publications at ASCO 2017 Preclinical toxicology data released at ESMO 2016 Four core platform patents issued Raised funding for Phase II metastatic pancreatic

  27. Slide 27: WALL STREET 12TH FLOOR NEW YORK, NY 10005 [email protected] TYMEINC.COM

    44 WALL STREET 12TH FLOOR NEW YORK, NY 10005 NASDAQ: TYME [email protected] TYMEINC.COM

Tyme Technologies — Investor Presentation (September 2017) on 6ix